Skip to main content

Advertisement

Table 4 Number and proportions of patients who used specific antihypertensive drugs and adjusted odds ratios for change

From: Change in antihypertensive drug prescribing after guideline implementation: a controlled before and after study

  Intervention Controls Intergroup comparison
  2001 2003 Adjusted* OR (95% CI) p-value 2001 2003 Adjusted* OR (95% CI) p-value Adjusted** OR (95% CI) p-value
  n (%)    n (%)     
Hypertension, N 2250 2969    5504 6717     
Diuretics 886 (39.4) 1143 (38.5) 0.97 (0.86, 1.08) 0.56 2207 (40.1) 2575 (38.3) 0.92 (0.85, 0.99) 0.02 1.06 (0.92, 1.21) 0.44
Beta-blockers 982 (43.6) 1312 (44.2) 1.04 (0.93, 1.16) 0.50 2335 (42.4) 2890 (43.0) 1.03 (0.96, 1.12) 0.35 1.01 (0.88, 1.15) 0.93
CCBs 560 (24.9) 747 (25.2) 1.04 (0.92, 1.18) 0.55 1349 (24.3) 1682 (25.0) 1.04 (0.95, 1.13) 0.43 0.99 (0.84, 1.14) 1.00
RAAS 738 (32.8) 1108 (37.3) 1.19 (1.06, 1.34) 0.004 1966 (35.7) 2724 (40.6) 1.24 (1.15, 1.34) <0.0001 0.96 (0.83, 1.10) 0.56
CHD, N 320 440    950 1148     
Diuretics 71 (22.2) 98 (22.3) 1.02 (0.71, 1.46) 0.92 171 (18.0) 229 (19.9) 1.05 (0.84, 1.33) 0.67 0.98 (0.64, 1.50) 0.92
Beta-blockers 235 (73.4) 350 (79.5) 1.39 (0.99, 1.96) 0.06 762 (80.2) 932 (81.2) 1.13 (0.90, 1.41) 0.29 1.25 (0.83, 1.88) 0.29
CCBs 103 (32.2) 113 (25.7) 0.75 (0.54, 1.03) 0.08 203 (21.4) 261 (22.7) 1.06 (0.86, 1.31) 0.59 0.70 (0.48, 1.03) 0.07
RAAS 43 (13.4) 86 (19.5) 1.57 (1.05, 2.34) 0.03 156 (16.4) 218 (19.0) 1.16 (0.92, 1.46) 0.20 1.34 (0.85, 2.12) 0.21
Diabetes, N 302 456    612 828     
Diuretics 115 (38.1) 184 (40.4) 1.10 (0.81, 1.49) 0.54 278 (45.4) 365 (44.1) 0.93 (0.75, 1.15) 0.49 1.19 (0.82, 1.72) 0.37
Beta-blockers 127 (42.1) 216 (47.4) 1.24 (0.93, 1.67) 0.15 275 (44.9) 379 (45.8) 1.03 (0.83, 1.28) 0.76 1.21 (0.84, 1.74) 0.31
CCBs 91 (30.1) 137 (30.0) 0.99 (0.72, 1.37) 0.96 148 (24.2) 223 (26.9) 1.13 (0.88, 1.45) 0.33 0.88 (0.59, 1.32) 0.54
RAAS 159 (52.6) 249 (54.6) 1.08 (0.80, 1.45) 0.64 284 (46.4) 427 (51.6) 1.27 (1.02, 1.57) 0.03 0.85 (0.59, 1.23) 0.39
  1. Prescription data was drawn from the national Prescription Register during a three-month period in 2001 and 2003.
  2. Abbreviations: CCBs, calcium channel blockers; RAAS, agents acting on renin-angiotensin-aldosterone system; CHD, coronary heart disease; OR, Odds ratio; CI, confidence interval.
  3. *Within-group analysis: Logistic regression, random effects model (physician as a random effect). Adjusted for patient's age and patient's sex.
  4. **Intergroup analysis: Logistic regression, random effects model (physician as a random effect). A product term between time (after versus before) and group (intervention versus control) was added in the model. Adjusted for patient's age and patient's sex.